RxDoctor Payments Data

Wayne Wu, MD

Internal Medicine · Alexandria, VANPI 1962554436

Payments from drug & device makers

$16,022in general payments, 2019–2025

Across 736 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • Sekisui Diagnostics LLC$1K
  • plus $6K from 54 others

What the payments were for

  • Consulting fees$6004%
  • Food & beverage$14,15488%
  • Education$240%
  • Gifts$1,2458%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)148$2,864
Novo Nordisk98$1,963
AstraZeneca77$1,567
Lilly USA, LLC72$1,435
Pfizer80$1,434
Sekisui Diagnostics LLC4$1,245
Medicure Pharma Inc.2$600
Astellas Pharma US Inc22$397
Johnson & Johnson(2 entities)20$375
Lundbeck LLC15$367
Amgen15$357
Merck25$342
Boehringer Ingelheim16$275
Gilead12$253
GSK11$203
Takeda Pharmaceuticals U.S.A., Inc.9$165
Otsuka America Pharmaceutical, Inc.9$160
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$156
Teva Pharmaceuticals USA, Inc.9$150
Harmony Biosciences LLC4$135
Amarin Pharma, Inc.8$130
Upsher-smith Laboratories LLC6$128
Exact Sciences4$110
Abbott5$104
Eisai Inc.5$70
Genentech USA, Inc.4$66
Medtronic3$64
Sumitomo Pharma America, Inc.3$58
Seqirus USA Inc3$53
Irhythm Technologies, Inc.2$46
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$41
IBSA Pharma Inc.2$39
Travere Therapeutics, Inc.1$35
Bayer2$34
Viiv Healthcare Company2$34
Corcept Therapeutics1$33
Dermira, Inc.2$31
Esperion Therapeutics, Inc.2$31
Amneal Pharmaceuticals LLC1$30
Novartis1$28
Shield Therapeutics Inc1$28
Davol Inc.1$26
E.r. Squibb & Sons, L.L.C.1$25
Calliditas Therapeutics US Inc.1$24
Novavax Inc1$24
Almatica Pharma LLC1$24
Bavarian Nordic A/s1$23
Supernus Pharmaceuticals, Inc.1$22
Actelion Pharmaceuticals US, Inc.1$21
Neos Therapeutics, LP1$20
Jazz Pharmaceuticals Inc.1$19
Pharming Healthcare, Inc.1$19
Bioventus LLC1$18
Vivus LLC1$17
Adlon Therapeutics L.p.1$17
Axsome Therapeutics, Inc.1$17
Phathom Pharmaceuticals, Inc.1$14
Dynavax Technologies Corporation1$14
Endo Pharmaceuticals Inc.1$14
Hikma Pharmaceuticals USA1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,022 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$127,695
Medicare patients
214
Services billed
2,660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$36,654
JardianceEmpagliflozin48$36,594
JanuviaSitagliptin Phosphate17$12,757
EliquisApixaban15$11,926
Atorvastatin Calcium269$2,074
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen45$1,814
SynthroidLevothyroxine Sodium31$1,800
Losartan Potassium134$1,339
Rosuvastatin Calcium63$1,022
Metformin Hcl111$1,015
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide24$983
Metoprolol Succinate79$948
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide20$760
Fluticasone Propionate13$736
Levothyroxine Sodium64$722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,963$36,65418 claims
Boehringer IngelheimJardiance$275$36,59448 claims
MerckJanuvia$342$12,75717 claims
PfizerEliquis$1,434$11,92615 claims
AbbVieSynthroid$2,864$1,80031 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$72264 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →